Marketed by American Regent, Inc., this product is identified by NDC 0517-0032 and is authorized under FDA application ANDA080737
Abstract Purpose of Review This review provides practitioners with an up-to-date overview of the efficacy and safety data of the currently approved weekly Nutrient-Stimulated Hormone (NuSH) therapies, semaglutide and tirzepatide, in managing obesity and weight-related comorbidities
Menstrual changes that have been anecdotally reported include: Irregular cycle timing or missed periods Heavier or lighter menstrual flow Changes in premenstrual symptoms Breakthrough bleeding between periods It is important to note that there is no official direct link established between tirzepatide's pharmacological mechanism and menstrual function
View abstract.
More broadly, compounds targeting core circadian regulators such as REV-ERBs, RORs, CRYs, and CK1 have already shown potential to fine-tune clock-controlled physiology in preclinical models (Solt et al., 2012
(9) A Nakamura, T Sugao, K Yamaue, M Kobatake, et al (1989) Involvement of spinal noradrenergic system in the mechanism of an antinociceptive effect of delta-sleep-inducing peptide (DSIP) Brain Research, 1989 Feb 20, Volume 480 (Issues 1-2), Pages 82-6